Lincoln National Corp’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-17,080
| Closed | -$13.3M | – | 680 |
|
|
2024
Q1 | $13.3M | Buy |
17,080
+1,789
| +12% | +$1.27M | 0.21% | 75 |
|
|
2023
Q4 | $8.91M | Buy |
15,291
+494
| +3% | +$288K | 0.16% | 83 |
|
|
2023
Q3 | $7.95M | Buy |
14,797
+1,351
| +10% | +$696K | 0.16% | 82 |
|
|
2023
Q2 | $6.31M | Buy |
13,446
+503
| +4% | +$211K | 0.12% | 102 |
|
|
2023
Q1 | $4.44M | Buy |
12,943
+207
| +2% | +$69.8K | 0.09% | 129 |
|
|
2022
Q4 | $4.66M | Sell |
12,736
-4,932
| -28% | -$1.75M | 0.11% | 122 |
|
|
2022
Q3 | $5.71M | Buy |
17,668
+1,207
| +7% | +$382K | 0.14% | 92 |
|
|
2022
Q2 | $5.34M | Buy |
16,461
+6,280
| +62% | +$1.89M | 0.13% | 99 |
|
|
2022
Q1 | $2.92M | Buy |
10,181
+525
| +5% | +$135K | 0.06% | 168 |
|
|
2021
Q4 | $2.67M | Buy |
9,656
+455
| +5% | +$115K | 0.05% | 180 |
|
|
2021
Q3 | $2.13M | Buy |
9,201
+251
| +3% | +$61.9K | 0.05% | 198 |
|
|
2021
Q2 | $2.05M | Buy |
8,950
+572
| +7% | +$115K | 0.04% | 199 |
|
|
2021
Q1 | $1.57M | Buy |
8,378
+464
| +6% | +$90.8K | 0.04% | 224 |
|
|
2020
Q4 | $1.34M | Buy |
7,914
+288
| +4% | +$43K | 0.04% | 231 |
|
|
2020
Q3 | $1.13M | Buy |
7,626
+969
| +15% | +$150K | 0.03% | 237 |
|
|
2020
Q2 | $1.09M | Buy |
6,657
+1,060
| +19% | +$163K | 0.03% | 227 |
|
|
2020
Q1 | $777K | Buy |
5,597
+937
| +20% | +$129K | 0.03% | 256 |
|
|
2019
Q4 | $612K | Buy |
4,660
+114
| +3% | +$13.2K | 0.02% | 353 |
|
|
2019
Q3 | $508K | Buy |
4,546
+88
| +2% | +$9.8K | 0.02% | 341 |
|
|
2019
Q2 | $494K | Buy |
4,458
+117
| +3% | +$13.8K | 0.02% | 324 |
|
|
2019
Q1 | $563K | Buy |
4,341
+139
| +3% | +$16.9K | 0.02% | 280 |
|
|
2018
Q4 | $487K | Buy |
4,202
+168
| +4% | +$18.8K | 0.02% | 272 |
|
|
2018
Q3 | $433K | Sell |
4,034
-150
| -4% | -$15K | 0.01% | 293 |
|
|
2018
Q2 | $357K | Sell |
4,184
-840
| -17% | -$69K | 0.01% | 327 |
|
|
2018
Q1 | $389K | Sell |
5,024
-2,943
| -37% | -$237K | 0.01% | 308 |
|
|
2017
Q4 | $673K | Buy |
7,967
+4,164
| +109% | +$354K | 0.02% | 310 |
|
|
2017
Q3 | $326K | Sell |
3,803
-8
| -0.2% | -$656 | 0.01% | 298 |
|
|
2017
Q2 | $313K | Buy |
3,811
+525
| +16% | +$42.8K | 0.01% | 262 |
|
|
2017
Q1 | $276K | Sell |
3,286
-262
| -7% | -$21K | 0.01% | 264 |
|
|
2016
Q4 | $261K | Buy |
3,548
+590
| +20% | +$43.9K | 0.01% | 247 |
|
|
2016
Q3 | $237K | Buy |
+2,958
| New | +$237K | 0.01% | 252 |
|
|
2016
Q1 | – | Sell |
-3,154
| Closed | -$256K | – | 252 |
|
|
2015
Q4 | $256K | Buy |
+3,154
| New | +$262K | 0.02% | 160 |
|
Other funds holding LLY
Lincoln National Corp's LLY Position: Q2 2024 in Review
Lincoln National Corp sold out of Eli Lilly (LLY) in Q2 2024, closing a stake of 17,080 shares — an estimated $13.3M sold.
Lincoln National Corp first reported a position in LLY in Q4 2015 and held it in 32 quarters. The position peaked at $13.3M in Q1 2024. 3,564 funds tracked by Wall St. Rank hold LLY as of Q2 2024.
- Lincoln National Corp reported no remaining Eli Lilly position as of Q2 2024 after selling out during the quarter.
- Lincoln National Corp sold 17,080 Eli Lilly shares in Q2 2024, an estimated $13.3M.
- Lincoln National Corp first reported a position in Eli Lilly in Q4 2015 and held it in 32 quarters.
- Lincoln National Corp's Eli Lilly position peaked at $13.3M in Q1 2024.
- 3,564 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2024.
Based on Lincoln National Corp's 13F filing for Q2 2024, filed 25 Jul 2024.